UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006412
Receipt number R000006468
Scientific Title Adherence to the ARB/CCB fixed dose combination tablets and ARB/CCB concomitant therapy, a randomized parallel trial on efficacy and safety
Date of disclosure of the study information 2011/09/27
Last modified on 2020/03/12 10:45:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Adherence to the ARB/CCB fixed dose combination tablets and ARB/CCB concomitant therapy, a randomized parallel trial on efficacy and safety

Acronym

Adherence to the ARB/CCB efficacy and safety study of both fixed dose combination tablets and concomitant usage.

Scientific Title

Adherence to the ARB/CCB fixed dose combination tablets and ARB/CCB concomitant therapy, a randomized parallel trial on efficacy and safety

Scientific Title:Acronym

Adherence to the ARB/CCB efficacy and safety study of both fixed dose combination tablets and concomitant usage.

Region

Japan


Condition

Condition

hypertension

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Hypertension ARB / CCB combination tablet clinical usefulness, ARB and CCB parallel group randomized trials comparing combination therapy

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

adherence

Key secondary outcomes

blood pressure, pulse rate


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

ARB / CCB combination tablet therapy administered for 2 months

Interventions/Control_2

CCB and ARB therapy is administered two months with a combination of antihypertensive therapy

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(a) Currently, ARB and CCB in combination with high blood pressure patients
(b) Patients with hypertension who are taking a combination tablet weight of each standard internal use
(c) Patients over 20 years of age at the time of obtaining informed consent
(d) Patients who obtained consent in writing of the study participants

Key exclusion criteria

(a) ARB, CCB administration of drugs contraindicated in patients with hypertension and other symptoms (irritability, and pregnant women)
(b) Patients deemed unsuitable for the doctor to conduct a study

Target sample size

440


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuki Kihara

Organization

Hiroshima University

Division name

Department of Cardiovascular Medicine

Zip code


Address

1-2-3 Kasumi, Minami-ku, Hiroshima

TEL

082-257-5540

Email



Public contact

Name of contact person

1st name
Middle name
Last name Takafumi Ishida

Organization

Hiroshima University

Division name

Department of Cardiovascular Medicine

Zip code


Address

1-2-3 Kasumi, Minami-ku, Hiroshima

TEL

082-257-5540

Homepage URL


Email

ishidat@hiroshima-u.ac.jp


Sponsor or person

Institute

Hiroshima University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Hiroshima Prefectural Hosp., Saiseikai Hiroshima Hosp., Saiseikai Kure Hosp., Kure Kyosai Hosp., Hiroshima City Hosp., JA Onomichi General Hosp., and other 40 Hospitals/Clinics

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

広島大学病院 他46施設


Other administrative information

Date of disclosure of the study information

2011 Year 09 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 04 Month 01 Day

Date of IRB

2011 Year 05 Month 06 Day

Anticipated trial start date

2011 Year 05 Month 10 Day

Last follow-up date

2014 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 09 Month 27 Day

Last modified on

2020 Year 03 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006468


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name